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ABSTRACT
Introduction: The American Academy of
Pediatrics (AAP) Committee on Infectious
Diseases issued updated guidance on
respiratory syncytial virus (RSV) prophylaxis in
2014. This report models the potential impact
of the new guidance on RSV outcomes in
preterm infants 29–34 weeks’ gestational age
(wGA) without chronic lung disease in the
United States.
Methods: The number of preterm infants was
estimated using 2012 natality data. Palivizumab
utilization prior to the 2014 guidance update
was estimated using 2013–2014 specialty
pharmacy utilization data. Low, moderate, and
high RSV hospitalization (RSVH) rates as well as
average hospital length of stay, intensive care
unit (ICU) admissions and mechanical
ventilation (MV) frequencies were derived
from published observational studies.
Palivizumab efficacy was derived from two
randomized clinical trials. RSV events that
would be attributable to the 2014 guidance
change were calculated for preterm infants
29–31 and 32–34 wGA.
Results: Annual number of infants 29–34 wGA
surviving the neonatal period was estimated at
123,687. Of these, an estimated 44,712 (37%)
would receive palivizumab based on the 2012
guidance. The annual number of RSVH among
infants 29–34 wGA would increase from 3580
under the 2012 guidance to 6166 under the
2014 guidance based on moderate rates. This
would result in an additional 24,440
hospitalization days, 1162 ICU admissions,
and 584 MV events among this population.
Conclusions: Based on published historical and
contemporary data on RSVH rates in preterm
infants 29–34 wGA, the 2014 AAP guidance is
expected to result in additional burden to the
healthcare system and families of preterm
infants. The impact of the new guidance will
be difficult to detect among the overall infant
population, particularly in settings without
routine testing for RSV, but the impact will be
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substantial for the small high-risk population





Respiratory syncytial virus (RSV) is the most
common cause of acute lower respiratory tract
infection and a major cause of hospitalizations
in young children [1]. In preterm infants, the
risk for severe RSV disease may lead to
hospitalization and, in some cases, intensive
care unit (ICU) admissions and mechanical
ventilatory support [2].
Palivizumab (MedImmune, Gaithersburg,
MD, USA) is a monoclonal antibody indicated
for the prevention of serious lower respiratory
tract disease caused by RSV in high-risk children
[3]. The American Academy of Pediatrics (AAP)
first published guidance for use of palivizumab
prophylaxis against RSV in 1998 and
subsequently updated them in 2000, 2003,
2006, 2009, and 2012 [4]. These later iterations
of the guidance narrowed the population
recommended for prophylaxis with a focus on
the increased risk and severity of RSV disease
associated with younger gestational age and
younger chronologic age [4, 5]. The 2012
Committee on Infectious Diseases (COID)
guidance recommended use of palivizumab
during the RSV season in preterm infants
B28 weeks’ gestational age (wGA) and
\12 months of age at RSV season start, 29–31
wGA and\6 months of age at RSV season start,
and 32–34 wGA and \3 months of age at RSV
season start. In addition to being\3 months of
age, infants 32–34 wGA were required to have
additional risk factors of either day care and/or
school-age siblings and could only receive
prophylaxis through 90 days of age [6]. In July
2014, the AAP issued updated guidance on RSV
prophylaxis that no longer recommended
palivizumab for preterm infants born 29–34
wGA without chronic lung disease (CLD),
asserting that ‘‘data regarding the risk of RSV
hospitalization for most preterm infants do not
support a benefit from prophylaxis [4]’’.
However, there is controversy surrounding
the elimination of palivizumab use among
infants 29–34 wGA. It has been argued that
the recommendation is not justified by the
studies cited by the COID [7, 8]. Boyce et al.
noted, ‘‘as academic physician-scientists, we
should carefully evaluate all of the existing
data and properly study proposed changes
before further restricting palivizumab use in
this voiceless and vulnerable population of
infants [7]’’. Similarly, the Institute of
Medicine’s Standards for Developing
Trustworthy Clinical Practice Guidelines
recommend that guidelines include
descriptions of the potential benefits and
harms [9].
The current analysis was designed to address
this need to evaluate the potential impact of the
AAP guidance change on RSV hospitalizations
in US preterm infants. By constructing a model
that elucidates the expected RSV outcomes for
preterm infants per the 2012 guidance
compared with the 2014 guidance, we were
able to estimate the potential impact of the
2014 AAP guidance on RSV outcomes in
preterm infants born 29–34 wGA without CLD
during the 2014–2015 and future RSV seasons.
METHODS
This article does not contain any new studies
with humans or animal subjects performed by
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any of the authors. Eight steps were taken to
model the potential impact of the 2014 AAP
guidance on RSV outcomes in preterm infants
29–31 wGA and\6 months chronologic age at
RSV season start and infants 32–34 wGA and
\90 days chronologic age with C1 risk factor
(Fig. 1). The first step involved identifying the
total number of US preterm births surviving the
neonatal period using the 2012 CDC Natality
File and Linked Birth/Infant Death Data File
[10]. In step 2, the number of preterm infants
29–31 and 32–34 wGA without CLD who would
have received palivizumab on the basis of the
2012 AAP guidance were estimated using
Specialty Distribution Network outpatient
usage data from the 2013–2014 RSV season.
For example, infants 32–34 wGA who would
have received palivizumab were assumed to be
less than 90 days of age during the RSV season
and had at least one additional risk factor
(daycare attendance or preschool-aged
siblings). Step 3 involved selecting low,
moderate, and high rates of RSV
hospitalization (RSVH) for infants born at
29–31 and 32–34 wGA who would have
received palivizumab under the 2012 guidance
and for infants 29–31 and 32–34 wGA who
would have not received palivizumab under the
2012 guidance. These hospitalization rates were
estimated using historical and contemporary
data from published studies [11–13]. The low,
moderate, and high RSVH rates for infants
29–31 wGA \6 months at RSV season start
who would have received palivizumab were
6.0%, 8.5%, and 12.0%, respectively. Among
infants 32–34 wGA\90 days of age during the
RSV season with one additional risk factor
(daycare attendance or preschool-aged
siblings), the low, moderate, and high RSVH
rates for infants that would have received
palivizumab were 5.0%, 6.5%, and 10.0%,
respectively [11]. Observational studies would
suggest that infants 29–31 wGA and 32–34 wGA
that would have not received palivizumab
(those [6 months at RSV season start for
29–31 wGA and those [90 days or those
\90 days during the season without risk
factors for infants 32–34 wGA) would have
lower RSVH risk than infants of the same wGA
group that was identified to receive
palivizumab. Therefore, the low, moderate,
and high RSVH rates were estimated to be
3.0%, 4.5%, and 6.0% for infants 29–31 wGA
and 2.0%, 3.5%, and 5.0% for infants 32–34
wGA, respectively. From these rates and the
known population sizes, the total annual
number of RSVH among preterm infants 29–31
and 32–34 were calculated.
Next, the RSVH relative risk reduction rates
associated with palivizumab use were applied in
step 4; a relative risk reduction of 78% for
preterm infants without bronchopulmonary
dysplasia was obtained from the IMpact study
findings, which are similar to recent results of
Blanken et al. [12, 14]. In step 5, the number of
hospitalizations with palivizumab use based on
the 2012 AAP guidance was calculated, and in
step 6, the number of hospitalizations with
palivizumab use based on the 2014 AAP
guidance was calculated. These estimates were
then subtracted to calculate the number of
additional hospitalizations expected from the
change in guidances (step 7). Finally, in step 8,
hospitalization length of stay, ICU rates, and
mechanical ventilation rates were applied from
an observational study of RSV-confirmed
hospitalizations among US preterm infants
29–35 wGA that did not receive palivizumab
[15–17]. The average hospitalization length of
stay was 10.4 days in infants 29–31 wGA and
8.4 days in infants 32–34 wGA and \90 days
chronologic age. The average ICU rates were
48.1% in infants 29–31 wGA and 41.4% in
infants 32–34 wGA and \90 days chronologic
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age. The average mechanical ventilation rates
were 25.9% in infants 29–31 wGA and 18.9% in
infants 32–34 wGA and \90 days chronologic
age.
The model was created using Excel 2013
(Microsoft Corporation).
RESULTS
The annual number of infants 29–34 wGA
surviving the neonatal period was estimated at
123,687 (29,106 infants 29–31 wGA and 94,581
infants 32–34 wGA; Fig. 2); this is
approximately 3% of the total annual number
of US births, 3,937,686. Of these infants, an
estimated 44,712 (37%) would have received
palivizumab based on the 2012 AAP guidance,
including 20,474 (70%) infants 29–31 wGA and
24,238 (26%) infants 32–34 wGA.
The low, moderate, and high estimates for
the total number of RSVH expected post-2014
guidance in infants 29–31 wGA were 1487,
2129, and 2975, respectively. The low,
moderate, and high estimates for the total
number of RSVH expected in infants 32–34
wGA were 2619, 4037, and 5941, respectively.
Using low estimates, the number of
additional RSVH that would be associated with
the 2014 guidance relative to the 2012 guidance
was 958 for infants 29–31 wGA and 945 for
infants 32–34 wGA (Fig. 3a). Based on moderate
estimates, the numbers of additional RSVH that
would be associated with the 2014 guidance
relative to the 2012 guidance were 1357 and
1229 for infants 29–31 and 32–34 wGA,
respectively (Fig. 3b). The high estimates for
the number of additional RSVH that would be
associated with the 2014 guidance relative to
the 2012 guidance were 1916 for infants 29–31
wGA and 1891 for infants 32–34 wGA (Fig. 3c).
The low estimates for the number of
additional RSVH that would be associated with
the 2014 guidance relative to the 2012 guidance
would result in an additional 9965 and 7940
hospitalization days, 461 and 391 ICU
admissions, and 248 and 179 mechanical
ventilation events, in infants 29–31 wGA and
32–34 wGA, respectively. The moderate
estimates for the number of additional RSVH
that would be associated with the 2014
guidance relative to the 2012 guidance would
result in an additional 14,117 and 10,322
hospitalization days, 653 and 509 ICU
admissions, and 352 and 232 mechanical
ventilation events, in infants 29–31 wGA and
32–34 wGA, respectively. Using high estimates,
this would result in an additional 19,930 and
15,881 hospitalization days, 922 and 783 ICU
admissions, and 496 and 357 mechanical
ventilation events in infants 29–31 wGA and
32–34 wGA, respectively.
bFig. 1 Modeling the potential impact of the 2014 AAP
guidance on RSV outcomes in preterm infants. AAP
American Academy of Pediatrics, CDC Centers for
Disease Control and Prevention, CLD chronic lung
disease, ICU intensive care unit, RSV respiratory syncytial
virus, wGA weeks’ gestational age
Fig. 2 US births by gestational age after adjusting for
neonatal deaths. wGA weeks’ gestational age
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Fig. 3 Estimated number of RSV hospitalizations among infants 29–31 wGA and 32–34 wGA based on a low, b moderate,
and c high estimates. AAP American Academy of Pediatrics, RSV respiratory syncytial virus, wGA weeks’ gestational age
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DISCUSSION
The current analysis quantifies the size of the
population affected by the 2014 policy change
and the range of expected additional RSV
hospitalizations in that population in the
absence of palivizumab use. This
quantification of the negative or serious
consequences of a new clinical practice
guidance is a recommended best practice by
the Institute of Medicine [9].
The data justifying the 2014 COID guidance
on palivizumab use have been questioned,
because they rely on reinterpretation of
historical studies that were previously cited by
AAP in support of palivizumab use, along with
newer studies conducted in years in which
palivizumab use was widespread [7, 11]. The
2014 AAP policy asserted, ‘‘In recent large cohort
studies of moderately preterm infants, the
majority of whom did not receive palivizumab,
2.5% to 4.9% required hospitalization for RSV
infection during the RSV season indicating that
more than 95% did not require hospitalization
[4]’’. A review of historical and contemporary
studies suggests that this range is an
underestimate, consistent with the fact that the
cited study did not employ active surveillance or
active testing for RSV.
Similarly, without active case-finding
methods to evaluate the burden of RSV disease
among US preterm infants, the overall adverse
outcomes and healthcare costs associated with
the new 2014 AAP guidance may be easily
overlooked due to the small number of infants
affected by this guidance. Preterm infants born
29–34 wGA comprise 3.1% of live births,
whereas those born 29–31 wGA represent only
0.7% [18]. The likelihood of an individual
physician or payer recognizing the impact of
the 2014 AAP guidance is low because of the
small number of preterm infants in individual
practices or healthcare plans. Additionally,
impact assessment will be particularly difficult
given that there is not routine testing for RSV,
even among preterm infants [11]. Findings from
the present study predict that the 2014 AAP
guidance will result in additional burden to the
healthcare system and families of preterm
infants.
CONCLUSION
Although the impact of the new guidance is
difficult to quantify among the overall infant
population, the impact may be significant for
this small, high-risk population, which, after
having incurred high costs for birth
hospitalization [19], will potentially be at risk
for additional adverse outcomes such as RSV
hospitalization, intensive care admission, and
mechanical ventilation.
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